Aibotics Closes NovaCore Labs Asset Buy; Issues 100M Shares to Two Executives
AIBT has more than doubled off its 52-week low of $0.
Summary
Aibotics closed its NovaCore Labs asset acquisition and agreed to issue up to 100 million common shares to two new executives, while committing to fund the subsidiary with $1M from a Regulation A offering that has not yet been raised.
Key Events · M&A and Partnerships · AIBT
-
NovaCore Labs Asset Acquisition Closed
Aibotics acquired PlayJamaica's robotics, drone, AI and mapping assets on October 14, 2026, including the NovaCore Labs brand, software and customer data, for 22,500 Series B Preferred shares with a $225,000 stated value.
-
Up to $3M Revenue Earn-Out
PlayJamaica can earn an additional $3,000,000 in Series B Preferred Stock in four $750,000 tranches if cumulative gross revenue reaches $500K, $1.5M, $3M and $5M within four years of closing.
-
100 Million Shares to Two Executives
Gregory Moore (NovaCore CEO) and Ryan Moore (VP) each receive up to 50,000,000 common shares vesting in three annual installments, plus cash bonuses of 10% and 8% of NovaCore net income capped at $500,000 each per year.
-
$1M Funding Obligation From Reg A
Aibotics committed to deploy $1,000,000 into NovaCore over 12 months using proceeds from a planned Regulation A offering; failure to fund within 30 days of notice lets PlayJamaica force a repurchase of the assets, repaid over 12 months at 8% interest under a secured note.
Analysis · AIBT · Life Sciences
Aibotics closed the acquisition of PlayJamaica's NovaCore Labs robotics, drone and mapping assets for 22,500 Series B Preferred shares ($225,000 stated value) plus up to $3M in revenue-based earn-outs. The bigger story is dilution: the two employment agreements grant Gregory Moore and Ryan Moore up to 50,000,000 common shares each — 100,000,000 shares total — vesting over three years. Against a $1.87M market cap and a stock at $0.0021, that is an enormous potential share issuance, and the company must fund NovaCore with $1M from a Regulation A offering it has not yet completed. If it fails to fund, PlayJamaica can force a repurchase of the assets and Aibotics would owe the money back with 8% interest under a secured note. This follows the August 10-Q's going-concern warning and $4.9M working capital deficit, so the funding obligation is a real constraint, not a formality.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.